Unstable amorphous or intermediate states lead to unpredictable crystallization and reduced shelf life. Achieving a defined, stable crystalline modification ensures consistent bioavailability and manufacturing reproducibility.

Unstable amorphous or metastable states lead to uncontrolled crystallization during storage. Maintaining a specific crystalline form prevents degradation and ensures consistent bioactivity.

Fluctuating systemic exposure leads to poor therapeutic efficacy or toxicity. Stabilizing release profiles ensures a predictable therapeutic window.